186 related articles for article (PubMed ID: 35965411)
21. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
22. Heat shock protein 27 knockdown using nucleotide‑based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells.
Shimada T; Tsuruta M; Hasegawa H; Okabayashi K; Shigeta K; Ishida T; Asada Y; Suzumura H; Koishikawa K; Akimoto S; Kitagawa Y
Oncol Rep; 2018 Mar; 39(3):1119-1124. PubMed ID: 29328475
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
24. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer.
Matsui Y; Hadaschik BA; Fazli L; Andersen RJ; Gleave ME; So AI
Mol Cancer Ther; 2009 Aug; 8(8):2402-11. PubMed ID: 19625496
[TBL] [Abstract][Full Text] [Related]
25. TP53INP1 as new therapeutic target in castration-resistant prostate cancer.
Giusiano S; Baylot V; Andrieu C; Fazli L; Gleave M; Iovanna JL; Taranger-Charpin C; Garcia S; Rocchi P
Prostate; 2012 Sep; 72(12):1286-94. PubMed ID: 22213058
[TBL] [Abstract][Full Text] [Related]
26. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
27. Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence.
Li F; Ling X; Chakraborty S; Fountzilas C; Wang J; Jamroze A; Liu X; Kalinski P; Tang DG
J Exp Clin Cancer Res; 2023 Aug; 42(1):213. PubMed ID: 37596619
[TBL] [Abstract][Full Text] [Related]
28. Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.
Luna Velez MV; Verhaegh GW; Smit F; Sedelaar JPM; Schalken JA
Oncogene; 2019 May; 38(19):3696-3709. PubMed ID: 30664691
[TBL] [Abstract][Full Text] [Related]
29. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
30. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
[TBL] [Abstract][Full Text] [Related]
31. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
32. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
Furukawa J; Wraight CJ; Freier SM; Peralta E; Atley LM; Monia BP; Gleave ME; Cox ME
Prostate; 2010 Feb; 70(2):206-18. PubMed ID: 19790231
[TBL] [Abstract][Full Text] [Related]
33. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
34. LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P.
You Z; Liu C; Wang C; Ling Z; Wang Y; Wang Y; Zhang M; Chen S; Xu B; Guan H; Chen M
Mol Cancer Ther; 2019 Dec; 18(12):2469-2479. PubMed ID: 31387890
[TBL] [Abstract][Full Text] [Related]
35. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
37. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion.
Mitra Ghosh T; Kansom T; Mazumder S; Davis J; Alnaim AS; Jasper SL; Zhang C; Bird A; Opanasopit P; Mitra AK; Arnold RD
J Pharmacol Exp Ther; 2022 Mar; 380(3):180-201. PubMed ID: 34949650
[TBL] [Abstract][Full Text] [Related]
38. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
Rocchi P; So A; Kojima S; Signaevsky M; Beraldi E; Fazli L; Hurtado-Coll A; Yamanaka K; Gleave M
Cancer Res; 2004 Sep; 64(18):6595-602. PubMed ID: 15374973
[TBL] [Abstract][Full Text] [Related]
40. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
